Senores Pharmaceuticals Ltd Q1 FY26 Results

Continuing the momentum from last year, we have started FY26 well, with healthy performance across segments during the quarter. We launched 2 own ANDA products in the Regulated Markets during the quarter. We also received the ANDA approval for 4 products during the quarter. We have a strong pipeline in place which we will launch over the next couple of years. Our moat lies in our ability to serve the government channel in addition to the retail channel in the US. This gives us considerable competitive advantage in the US market. A large part of our product pipeline has potential to cater to the government contracts. Our capability to manufacture and supply controlled substances in US is another differentiator for us. Our CDMO / CMO segment is also scaling up as planned. We are adding new contracts and increasing the share of pocket from existing customers. The contracts in hand give us good visibility for the year ahead. In the Emerging Markets, our changing product portfolio and go-to-market strategies are resulting in improved profitability. Our Branded Generics segment is witnessing significant uptick in momentum. On the back of increasing field force, our monthly revenue run rate has more than doubled versus last year. We expect to be a pan-I/ndia player by the end of FY26. We are also pleased to report positive Operating Cash Flow of Rs 11 crores for Q1FY26. We expect to sustain and build on the cash flow trajectory going forward. Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on three key pillars — (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; and (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets